Kuda Therapeutics, Inc.
Salt Lake City, UT Doing business as Kuda Therapeutics
- UEI
- WAH4VVM57875
- CAGE
- 7P0K9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 199 Dorchester Dr E, Salt Lake City, UT 84103, USA
- Website
- kudatherapeutics.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Advancing a novel, orally available ferroptosis inducer for the treatment of VHL disease | Defense Health Agency | $5,599,141 | |
| Ferroptosis as a therapeutic strategy for clear cell ovarian cancer | Defense Health Agency | $420,000 | |
| The investigation of ferroptosis as a novel therapeutic paradigm for kidney cancer | Defense Health Agency | $560,000 | |
| Development of a novel dual HIF-? Inhibitor and inducer of ferroptosis for kidney cancer - abstract kidney cancer is the… | National Cancer Institute | $4,100,000 | |
| Development of a novel class of selective HIF-2A inhibitors for kidney cancer | National Cancer Institute | $355,002 |
About Kuda Therapeutics, Inc.
Kuda Therapeutics, Inc. is a woman-owned small business based in Salt Lake City, Utah, focused on medical research and therapeutic development, with a specific emphasis on investigating ferroptosis as a potential treatment strategy for various cancer types. Registered in SAM.gov since July 31, 2016, the company operates as a for-profit corporate entity and has been actively pursuing federal grant awards to support advanced medical research initiatives. The organization appears to specialize in developing innovative therapeutic approaches targeting specific cancer mechanisms, with a particular interest in understanding and leveraging ferroptosis as a novel treatment paradigm.
The company has secured multiple federal grant awards from the Defense Health Agency, primarily targeting research on ferroptosis in different cancer types. Specific research projects include investigating ferroptosis as a therapeutic strategy for clear cell ovarian cancer, a novel orally available ferroptosis inducer for von Hippel-Lindau (VHL) disease treatment, and exploring ferroptosis as a therapeutic approach for kidney cancer. These grants, ranging from $420,000 to support basic, translational, and clinical research, demonstrate Kuda Therapeutics' commitment to advancing medical research with potential implications for military service members, veterans, and their families. The research projects are designed to make significant advances in military medicine by developing innovative treatment strategies that could improve health outcomes for these populations, with a particular focus on understanding and potentially treating specific cancer types through the emerging field of ferroptosis research.
Quick answers
What is Kuda Therapeutics, Inc.'s UEI?
Kuda Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is WAH4VVM57875.
What is Kuda Therapeutics, Inc.'s CAGE code?
Kuda Therapeutics, Inc.'s CAGE code is 7P0K9.
What is Kuda Therapeutics, Inc.'s primary NAICS code?
Kuda Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Kuda Therapeutics, Inc. located?
Kuda Therapeutics, Inc.'s physical address in SAM.gov is 199 Dorchester Dr E, Salt Lake City, UT 84103, USA.
Is Kuda Therapeutics, Inc. registered in SAM.gov?
Yes. Kuda Therapeutics, Inc.'s SAM.gov registration is active through August 17, 2027.
What is Kuda Therapeutics, Inc.'s most recent federal award?
Kuda Therapeutics, Inc.'s most recent federal grant award is Advancing a novel, orally available ferroptosis inducer for the treatment of VHL disease (HT94252510408), from Defense Health Agency, on June 1, 2025.
On GovTribe
See Kuda Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors